Sarcomatoid mesothelioma is the most aggressive subtype of mesothelioma, a cancer that develops in the thin lining surrounding the lungs, abdomen, or heart. It accounts for roughly 10 to 20 percent of all mesothelioma diagnoses and is defined by its distinctive spindle-shaped cancer cells, which grow and spread faster than the cells found in other mesothelioma subtypes. Because of this aggressive behavior, sarcomatoid mesothelioma carries a shorter life expectancy and is generally treated with systemic therapies rather than surgery.
What Makes Sarcomatoid Cells Different
Mesothelioma is classified into three subtypes based on what the cancer cells look like under a microscope: epithelioid (the most common and slowest-growing), biphasic (a mix), and sarcomatoid (the rarest and most aggressive). Sarcomatoid cells are elongated and spindle-shaped, packed densely together with frequent signs of rapid division. Some cases also show oversized or oddly shaped cells with multiple nuclei, sometimes called “bizarre” cells by pathologists.
This unusual cell shape creates a real diagnostic challenge. Pathologists typically identify mesothelioma by testing tumor tissue for specific protein markers that are characteristic of mesothelial cells (the cells that line the lungs and chest cavity). But sarcomatoid mesothelioma expresses these markers inconsistently. Calretinin, widely considered the most reliable marker for identifying mesothelioma, shows up in only about 31 percent of sarcomatoid cases, compared to the vast majority of epithelioid cases. This means sarcomatoid mesothelioma can be mistaken for other spindle-cell cancers, including a type of lung cancer that looks similar under the microscope.
Why It’s Hard to Diagnose
Distinguishing sarcomatoid mesothelioma from sarcomatoid lung carcinoma is one of the trickiest problems in thoracic pathology. Both cancers can produce spindle-shaped cells in the chest lining, and neither reliably lights up with the standard protein markers that would normally separate them. Pathologists use a combination of staining techniques, looking for markers associated with mesothelial cells while also testing for markers that would point to a lung cancer origin. When a spindle-cell tumor in the pleura stains positive for certain proteins called cytokeratins and mesothelial markers, and negative for epithelial markers associated with lung cancer, the diagnosis leans toward mesothelioma.
In practice, though, the overlap can be significant. Cytokeratin staining, which is positive in up to 93 percent of sarcomatoid mesothelioma cases, sometimes only shows up in a handful of cells. And the epithelial markers that should help rule out lung cancer can also be absent in sarcomatoid lung carcinoma. This means diagnosis often requires large tissue samples (not just a needle biopsy), expert pathology review, and careful correlation with imaging and clinical history. Misdiagnosis or delayed diagnosis is not uncommon.
Symptoms and How They Develop
Like all forms of mesothelioma, sarcomatoid mesothelioma is linked to asbestos exposure, and symptoms can take 10 to 50 years to appear after that exposure. This long latency period means most people are diagnosed in their 60s or 70s, often decades after working in construction, shipbuilding, manufacturing, or other industries where asbestos was common.
Early symptoms tend to be vague and easy to attribute to other conditions:
- Coughing
- Shortness of breath
- Chest pain
As the disease progresses, symptoms become more severe and harder to ignore. Persistent coughing and worsening breathlessness are common, along with coughing up blood, hoarseness, unexplained weight loss, decreased appetite, nausea, fatigue, and general weakness. Because sarcomatoid mesothelioma grows quickly, the window between mild symptoms and significant illness can be shorter than with other subtypes.
Treatment Approach
The treatment of sarcomatoid mesothelioma differs significantly from the epithelioid subtype. Current national guidelines recommend systemic therapy (medications that travel through the bloodstream to reach cancer throughout the body) as the primary treatment for sarcomatoid mesothelioma, regardless of how early the cancer is caught. This is a notable distinction: even patients with early-stage disease are generally steered away from surgery.
The preferred first-line treatment is a combination of two immunotherapy drugs, nivolumab and ipilimumab, which work by helping the immune system recognize and attack cancer cells. This combination received FDA approval based on clinical trial data showing improved survival in mesothelioma patients. Chemotherapy with cisplatin and pemetrexed, long the standard for mesothelioma, is still an option but is listed as a secondary recommendation for sarcomatoid cases rather than the preferred choice. Other chemotherapy combinations, including gemcitabine with a platinum drug, or single-agent treatments, may be used in specific situations.
Immunotherapy has been a meaningful shift for sarcomatoid mesothelioma patients. Historically, this subtype responded poorly to chemotherapy compared to epithelioid mesothelioma. Early evidence suggests that sarcomatoid tumors may actually respond relatively well to immunotherapy, which has narrowed the treatment gap between subtypes somewhat.
Why Surgery Is Rarely Recommended
For epithelioid mesothelioma caught early, surgery to remove visible tumor is sometimes part of a multimodal treatment plan. For sarcomatoid mesothelioma, surgery is generally not recommended. National guidelines direct patients with sarcomatoid histology toward systemic therapy alone, regardless of clinical stage.
The reasoning comes down to risk and benefit. Studies examining surgical outcomes in sarcomatoid mesothelioma have found high perioperative mortality: 6 percent of patients died within 30 days of surgery, and 21.4 percent died within 90 days. Those numbers are striking, especially given the limited evidence that surgery extends survival in this subtype. The only randomized trial specifically studying radical surgery for mesothelioma (the MARS trial) found no survival benefit for the most aggressive surgical option, extrapleural pneumonectomy, though the trial had significant limitations including a small sample size.
Given these outcomes, most cancer centers reserve surgery for carefully selected patients and rely on multidisciplinary tumor boards to weigh the risks. For the majority of sarcomatoid mesothelioma patients, the focus is on systemic treatment to control the disease and manage symptoms.
Prognosis and What to Expect
Sarcomatoid mesothelioma carries the shortest survival of the three mesothelioma subtypes. Median survival after diagnosis has historically been around 6 to 12 months, though this varies based on overall health, stage at diagnosis, and response to treatment. The introduction of immunotherapy has offered some improvement, and individual outcomes can differ substantially from statistical medians.
Because the disease progresses quickly, palliative care, which focuses on symptom relief and quality of life, is an important part of the treatment plan from the start. This doesn’t mean giving up on treatment. It means managing breathlessness, pain, fatigue, and nutrition alongside whatever systemic therapy is being used. Many cancer centers now integrate palliative specialists into the care team from the point of diagnosis for aggressive cancers like this one.